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Transcatheter Mitral and Pulmonary Valve Therapy
Nicolo Piazza, MD,* Anita Asgar, MD,† Reda Ibrahim, MD,‡ Raoul Bonan, MD‡
Rotterdam, the Netherlands; London, United Kingdom; and Montreal, Quebec, Canada
As the percentage of seniors continues to rise in many populations around the world, the already challenging
burden of valvular heart disease will become even greater. Unfortunately, a significant proportion of patients
with moderate-to-severe valve disease are refused or denied valve surgery based on age and/or accompanying
comorbidities. Furthermore, because of advances in pediatric cardiology, the number of adult patients with con-
genital heart disease is on the rise and over time, these patients will likely require repeat high-risk surgical pro-
cedures. The aim of transcatheter valve therapies is to provide a minimally invasive treatment that is at least as
effective as conventional valve surgery and is associated with less morbidity and mortality. The objective of this
review was to provide an update on the clinical status, applicability, and limitations of transcatheter mitral and
pulmonary valve therapies. (J Am Coll Cardiol 2009;53:1837–51) © 2009 by the American College of
Cardiology Foundation
ublished by Elsevier Inc. doi:10.1016/j.jacc.2008.12.067i
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che prevalence of moderate-to-severe valvular heart disease
s highly age-dependent, ranging from an estimated 0.7% in
8- to 44-year-olds in the U.S. to 13.3% among those 75
ears of age or older (1). Given the aging population in
any developed countries, the percentage of seniors with
ignificant heart valve disease is projected to rise substan-
ially in coming years. Moreover, an increasing number of
dult patients with congenital heart disease will contribute
urther to the growing number of patients who will require
igh-risk surgical procedures in the future (2).
Although surgical heart valve repair or replacement re-
ains the standard of care for patients with hemodynami-
ally significant valvular heart disease, the European Heart
urvey demonstrated that up to one-third of patients with
ymptomatic severe valve disease are denied surgery (3).
his includes about one-half of patients with severe symp-
omatic mitral regurgitation (MR) and one-third of elderly
atients with severe, symptomatic aortic stenosis who are
enied or refused surgery (4,5). Compared with those who
nderwent surgery, these patients were typically older, had
oderate impairment of ejection fraction (31% to 60%), and
ad more noncardiac comorbidities than did patients un-
ergoing valve surgery. Whether denying surgery in these
atients was justified or not, the challenges of managing
hese patients will only increase in the coming years as the
umber of patients considered for surgery continues to rise.
inally, the situation is further complicated by the increas-
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008, accepted December 23, 2008.ng prevalence of adults with congenital heart disease. It is
afe to assume that some of these patients will require
igh-risk surgical valve procedures in the future (2). In an
ffort to address the challenges ahead, researchers have been
eveloping new options for a rapidly growing pool of
atients in whom heart valve replacement or repair may be
eneficial, but for whom surgical intervention is considered
oo high risk. The goal of transcatheter valve therapy is to
rovide a treatment modality that is less invasive, associated
ith equal or greater efficacy compared with standard
urgery, and is potentially safer than more invasive
rocedures.
Conceptualization of a catheter-mounted heart valve
merged 3 decades ago (6,7). In 1992, investigators pro-
osed transcatheter deployment of a stent-mounted porcine
ioprosthetic valve in an animal model (8). In 2000,
onhoeffer et al. (9) reported the first percutaneous implan-
ation of a stent-mounted bovine jugular vein valve in the
ulmonary position. Soon thereafter, Cribier et al. (10)
escribed the first-in-man percutaneous aortic valve im-
lantation and subsequently, the first percutaneous mitral
alve repair was performed.
Historically, randomized controlled trials are not required
y the U.S. Food and Drug Administration for the approval
f surgical heart valve prostheses. Instead, objective perfor-
ance criteria, established by large retrospective observa-
ional studies, have been used to assess the safety and
fficacy of surgical valve prostheses (11). The Food and
rug Administration, however, views percutaneous valve
echnology as enough of a departure from the current
tandard of clinical care that randomized controlled
linical trials will be required to evaluate safety and
ffectiveness.
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Transcatheter Mitral and Pulmonary Therapies May 19, 2009:1837–51Generally speaking, a trial
comparing transcatheter valve
therapy to surgical therapy will
require superiority assessment for
safety and noninferiority or even
superiority assessment for effi-
cacy. On the other hand, a trial
comparing transcatheter valve
therapy with medical therapy in
nonoperable patients will require
proof of superiority for both
safety and efficacy.
The objective of this review
as to provide a comprehensive update on the current
linical status, applicability, and limitations of transcatheter
itral and pulmonary valve therapies.
ranscatheter Mitral Valve Repair
ne of the most common forms of valvular heart disease
1,3), MR affects an estimated 9.3% of the population age
75 years (1). Furthermore, 15% to 20% of patients with
eart failure and 12% of patients 30 days after myocardial
nfarction (MI) have moderate to severe MR (12,13). Even
ild-to-moderate degrees of MR that occur after an acute
I will adversely affect 5-year survival, yet the potential
enefits of surgically or percutaneously treating mild or
oderate degrees of MR are unknown.
Proper functioning of the mitral valvular complex de-
ends on the structural and functional integrity of its
ndividual components (i.e., the mitral annulus, leaflets,
hordae tendineae, papillary muscles, left atrial and left
entricular [LV] walls in continuity with the leaflets, and
apillary muscles, respectively). MR can be classified as
rimary, that is, an abnormality of the mitral valve apparatus
e.g., degenerative mitral valve disease), or secondary (or
unctional), as a result of an ischemic or nonischemic dilated
ardiomyopathy in the setting of anatomically normal mitral
alvular leaflets and chords. It is axiomatic that a thorough
nderstanding of the mechanisms of MR and its surgical
reatment are essential to the conceptualization, develop-
ent, and understanding of transcatheter mitral valve tech-
iques. Despite the superior long-term outcomes associated
ith mitral valve repair rather than mitral valve replacement
14), mitral valve repair is performed in only one-third of
atients undergoing mitral valve surgery (15).
Annuloplasty is the cornerstone of mitral valve repair and is
ssential for the surgical correction of functional MR. For
epair of degenerative mitral valve disease, failure to perform a
oncomitant annuloplasty procedure adversely affects the long-
erm durability of the repair (16,17). Annuloplasty may be used
oncomitantly with leaflet repair (resection, sliding annulo-
lasty) or chordal reconstruction (transposition, artificial
hords).
The Alfieri procedure involves suturing the free edges of
Abbreviations
and Acronyms
LV  left
ventricle/ventricular
MI  myocardial infarction
MR  myocardial
regurgitation
RVOT  right ventricular
outflow tract
RV  right
ventricle/ventricularhe middle anterior (A2) and posterior (P2) leaflets of the oitral valve. This produces a double orifice mitral valve. The
rocedure can be used to treat degenerative or functional
R. Like leaflet repair, the Alfieri procedure requires
oncomitant annuloplasty to avoid repair failure (18,19).
his concept, however, has been challenged by Maisano et
l. (20), who reported that isolated surgical edge-to-edge
epair performed intentionally without annuloplasty has
cceptable midterm results for degenerative and functional
itral regurgitation (5-year freedom from recurrent MR
rade 2 and reoperation 90  5%). The results support
he use of an isolated transcatheter edge-to-edge repair
echnique. After mitral valve surgery, 15% to 30% of
atients have persistent/recurrent MR2 (17,21–24), yet
significant proportion of these patients remains asymp-
omatic and does not require reoperation (93% to 96%
reedom from reoperation at 10 years) (16,25).
Strategies for transcatheter mitral valve repair (reviewed
n Table 1) include: 1) creation of a double orifice mitral
alve using percutaneous edge-to-edge techniques with a
lip device (e.g., MitraClip [Evalve, Inc., Menlo Park,
alifornia]) or stitch (e.g., MOBIUS [Edwards Lifesciences
orp., Irvine, California]); 2) remodeling of the annulus of
he mitral valve by suture-based techniques (e.g., Percuta-
eous Suture Annuloplasty [Mitralign, Inc., Tewksbury,
assachusetts], AccuCinch [Guided Delivery Systems,
anta Clara, California]), or application of radiofrequency
nergy (e.g., QuantumCor Endovascular Device [Quantum-
or, San Clemente, California]); 3) remodeling of the
itral valvular complex by transventricular (e.g., iCoapsys
Myocor, Maple Grove, Minnesota]) or transatrial (e.g.,
ercutaneous Septal Sinus Shortening [PS3] system [Am-
le Medical, Foster City, California]) devices; and
) remodeling of the annulus of the mitral valve by devices
mplanted in the coronary sinus (e.g., Percutaneous Mitral
nnuloplasty [PTMA] device [Viacor, Wilmington, Mas-
achusetts]; CARILLON Mitral Contour System [Cardiac
imensions Inc., Kirkland, Washington]; and MONARC
ystem [Edwards Lifesciences Corp.]).
There are 2 important points. First, unlike pulmonic
alve disease, treatment of MR has the potential to have an
xtraordinary impact on clinical practice due to the higher
revalence of the disease. Second, as opposed to the endolu-
inal treatment of aortic valve disease, significant and
obust clinical results from transcatheter mitral valve ther-
pies cannot be expected in the short term, due both to the
omplexities of the anatomy and the pathophysiology of
R. In addition, as with conventional surgery, a combina-
ion of more than 1 transcatheter mitral valve technique may
e required to achieve satisfactory results.
dge-to-Edge Techniques
itraclip. The Mitraclip (Evalve, Inc.) uses a tri-axial
atheter system with a clip device at its distal tip (Figs. 1A
nd 1B). The goal of the procedure is to create a double-
rifice mitral valve similar to the Alfieri surgical technique
(
t
a
2
o
u
e
r
c
s
p
m
d
c
c
t
t
v
1
p
i
v
O
(
s
w
w
d
m
p
d
h
w
m
t
a
N
T
d
g
M
O
*
i atest r
right in
1839JACC Vol. 53, No. 20, 2009 Piazza et al.
May 19, 2009:1837–51 Transcatheter Mitral and Pulmonary TherapiesFig. 1C). The guide catheter is 24-F at its proximal end,
apering to 22-F at its distal end. The system is delivered via
standard transseptal approach into the left atrium. The
-armed clip is a polyester-covered device. Each clip arm
pposes against a multipronged friction element that allows
p to 8 mm of mitral valve leaflet to be grasped securely on
ach side. Once clip placement and real-time echocardiog-
aphy confirm adequate reduction of MR (grade 2), the
lip device is detached from the delivery catheter. Use of
tandardized echocardiographic protocols can greatly im-
rove procedural times and ease of clip placement (26).
The safety and feasibility of the Mitraclip in a porcine
odel has been reported (27,28). The EVEREST (En-
ovascular Valve Edge-to-Edge Repair Study) phase I
linical study is completed and EVEREST phase II is
urrently enrolling patients with degenerative or func-
ional MR (moderate-severe [3] or severe [4]). Pa-
ients are being randomized to Mitraclip versus mitral
alve surgery (2:1). Preliminary results from the initial
07 patients—55 patients from the EVEREST I and 52
atients from the ongoing EVEREST II study—
verview of Transcatheter Mitral Valve Therapies
Table 1 Overview of Transcatheter Mitral Valve Therapies
Technology
(Manufacturer) General Approach Indication Vascular A
Mitraclip (Evalve) Edge-to-edge repair
(“percutaneous
Alfieri stitch”)
Degenerative or
functional MR
Standard tran
MOBIUS Leaflet
Repair System
(Edwards)
Edge-to-edge repair
(“percutaneous
Alfieri stitch”)
Degenerative or
functional MR
Standard tran
Mitralign
(Accelerated
Technologies)
“Suture”
annuloplasty
Degenerative or
functional MR
FA (retrograd
to LV)
AccuCinch (Guided
Delivery Systems)
“Suture”
annuloplasty
Functional MR RIJ vein (acce
and FA (re
access to
QuantumCor
radiofrequency
technology
“Radiofrequency”
annuloplasty
Functional MR Under investi
iCoapsys (Myocor) Transventricular
remodeling
Functional MR Subxiphoid p
approach
Percutaneous Septal
Sinus Shortening
Device (Ample
Medical)
Transatrial
remodeling
Functional MR RIJ vein (acce
and stand
transsepta
MONARC System
(Edwards)
Coronary sinus
device
Functional MR RIJ vein (acce
Percutaneous Mitral
Annuloplasty
(PTMA) device
(Viacor)
Coronary sinus
device
Functional MR RIJ vein (acce
The CARILLON Mitral
Contour System
(Cardiac
Dimensions)
Coronary sinus
device
Functinal MR RIJ vein (acce
The number of symbols indicates the relative technical demands of the procedure; 3 symbols
ndicates the potential for coronary artery occlusion with the device; 3 symbols indicates the gre
CS  coronary sinus; FA  femoral artery; LV  left ventricle; MR  mitral regurgitation; RIJ ndicated that 84 patients (79%) had degenerative mitral Ialve disease and 23 patients (21%) had functional MR.
ne or more clips were implanted in 96 patients (90%)
65 patients, 1 clip; 31 patients, 2 clips). Acute procedural
uccess, defined by clip placement and MR grade 2,
as observed in 81 of 96 patients (84%) (Table 2). There
as 1 in-hospital death (0.9%) unrelated to the clip
evice. At 30 days, 97 patients (91%) were free from
ajor adverse events. Ten patients (9%) experienced
artial clip detachment and 9 of these occurred within 30
ays, but without any major adverse events. Length of
ospital stay averaged 3.2 days, and 104 patients (97%)
ere discharged without the need for home care. After a
edian follow-up of 386 days, 75 patients (70%) did not have
o resort to surgery for device failure. Among patients with
cute procedural success, 73% of patients had improvement in
ew York Heart Association functional class at 12 months.
he 2-year follow-up of the first patient showed a sustained
ecrease in the severity of mitral regurgitation (reduced from
rade 4 to 1) and favorable positive remodeling indexes after
itraclip implantation (29).
To date, approximately 400 patients (EVEREST I and
Technical Aspects
Study
Phase
Technical
Demand*
Coronary Artery
Compromise†
Dependency on
Imaging for
Implantation
al Phase II () () Echocardiography 
fluoroscopy
al Phase I () () Echocardiography 
fluoroscopy
ss Phase I () () Echocardiography 
fluoroscopy
CS)
de
Pre-clinical Not available () Echocardiography 
fluoroscopy
Pre-clinical Not available () Under investigation
ial Phase I () () Echocardiography 
fluoroscopy
CS) Phase I () () Fluoroscopy 
echocardiography
CS) Phase II () () Fluoroscopy 
echocardiography
CS) Phase II () () Fluoroscopy 
echocardiography
CS) Phase I () () Fluoroscopy 
echocardiography
e the most demanding and 1 symbol indicates the least demanding. †The number of symbols
isk and a  symbol indicates no risk.
ternal jugular.ccess
ssept
ssept
e acce
ss to
trogra
LV)
gation
ericard
ss to
ard
l
ss to
ss to
ss to
indicatI) have been implanted with the Mitraclip. Initial results
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Transcatheter Mitral and Pulmonary Therapies May 19, 2009:1837–51re encouraging, but they remain inferior to surgical results.
mportantly, clip failure is well tolerated and does not
reclude surgical mitral valve repair. In rare instances,
xcessive fibrous reaction around the clip device may pro-
ibit mitral valve repair and lead to the necessity for mitral
alve replacement.
OBIUS Leaflet Repair system. Although similar in
oncept to the Mitraclip device, the Edwards MOBIUS
eaflet Repair system (Edwards Lifesciences Corp.) uses a
percutaneous” stitch to create a double-orifice mitral valve
Fig. 2). The procedure is performed under intracardiac
chocardiography and fluoroscopy (30). A standard trans-
eptal approach is used to access the left atrium with a 10-F
atheter. The therapy catheter is used to vacuum, capture,
nd deliver a 4-0 polypropylene suture to the free edges of
he mitral valve. Finally, a 7-F fastener catheter deploys a
itinol suture clip and cuts the excess suture. In case of
nadequate results, it is possible to remove the suture before
eploying the clip.
Feasibility studies in animals provided encouraging re-
ults (31). Outcomes from the initial 15 patients treated
ith the MOBIUS Leaflet Repair system demonstrated
cute procedural success in about two-thirds (9 of 15) of
atients, with the remainder undergoing successful mitral
alve surgery (Table 2). The degree of MR improved from
mean grade of 4 to 2 at discharge. At 30-day
ollow-up, fewer than one-half of the total patients enrolled
6 of 15) had a successful stitch in place. Of the 6 stitch
esponders, 3, 2, and 1 patients had a 1, 2, and 3
eduction in the severity of MR, respectively. The poor
ntermediate durability results led investigators to suspend
urther experimentation with the device for this particular
ndication.
irect Annuloplasty Techniques
he gold standard for surgical annuloplasty is to implant an
ndersized, rigid, and complete prosthetic ring (21), but
oth semi-rigid and flexible rings abolish normal annular
ynamics and freeze the posterior mitral leaflet in the
emi-open position. Surgical suture annuloplasty was devel-
ped to reduce the size of the annulus while maintaining
hysiological annular and leaflet motion. Evidence suggests
hat a 20% relative reduction of the septal-lateral dimen-
ions of the mitral annulus can significantly reduce the
everity of regurgitation (32). This approach has acceptable
-year durability results, including an 82% rate of freedom
rom significant MR, a 95% rate for freedom from reopera-
ion, and an actuarial survival rate of 87.2% at 6.4 years (33).
itralign. In an effort to imitate a surgical suture annulo-
lasty procedure, the Mitralign system (Mitralign, Inc.)
elies on a single 14-F femoral arterial access whereby a
herapy catheter with a deflectable end is inserted retrograde
cross the aortic valve into the LV and positioned in a
ubvalvular mitral position (Fig. 3A). The deflectable cath-Figure 1 The Evalve Mitraclip (Evalve, Inc.)
(A) Clip device on distal tip of tri-axial catheter delivery system. (B) Illustrated
components of clip device grasping mitral valve leaflet. (C) Animal pathology
specimen of the mitral valve with clip resulting in a double-orifice mitral valve.ter helps direct guidewires and anchors pledgets across the
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May 19, 2009:1837–51 Transcatheter Mitral and Pulmonary Therapiesitral annulus from the LV to the left atrium. The anchors
re tethered and put into tension to decrease the septal-
ateral dimensions of the mitral annulus (Figs. 3B and 3C).
utside of the U.S., a small number of patients have
ndergone preliminary studies examining only catheter
ositioning and wire placement. A European-based pilot
linical Results
Table 2 Clinical Results
Technology Study Phase
Procedural
Success
% of Pat
and
Evalve Mitraclip Phase II (n  107) 84%  grade
MOBIUS Leaflet Repair System Phase I (n  15) 60%  grade
50% (
Edwards MONARC System Phase I (n  79) 82% Not avail
Viacor Percutaneous Mitral
Annuloplasty device
Phase I (n  19) 68% 1 grade
(imme
CARILLON Cardiac Dimensions
Coronary Sinus
Annuloplasty Device
Phase I (n  43) 70% 1 grade
(imme
I  myocardial infarction; MR  myocardial regurgitation; NYHA  New York Heart Association
Figure 2 The MOBIUS Leaflet Repair Suture Delivery System (E
(A) A 17-F guide catheter, (B) a 10-F therapy catheter, and (C) a 7-F fastener cath
men of the mitral valve with suture clip resulting in a double-orifice mitral valve. (E
used to suction the mitral leaflet and deliver the suture. (F) Nitinol suture-clip that
** denote the anterior and posterior mitral valve leaflets, respectively.mplant study in humans was recently initiated in the last
uarter of 2008.
ccuCinch. The AccuCinch device (Guided Delivery Sys-
ems) uses a commercially available catheter with a propri-
tary design allowing retrograde access to the subannular
pace of the mitral valve. The goal is to deliver anchors
With Procedural Success
tion in Severity of MR Clinical Improvement 30-Day Outcomes
84% (immediate) 73% of patients had at least
1 grade improvement in
NYHA functional class
91% free of major
adverse events
83% (immediate) and
s)
Not available Not available
Not available 90% free of
death, MI, and
tamponade
tion in MR: 68% Not available Not available
tion in MR: 80% 75% of patients had at least
1 grade improvement in
NYHA functional class
Not available
ds Lifesciences Corp.)
esigned to deploy the suture clip and cut the suture. (D) Animal pathology speci-
ed view of the end of therapy catheter showing an orifice (white arrow) that is
livered over the suture before the suture is cut above the suture-clip. The * andients
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2 MR:
2 MR:
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Transcatheter Mitral and Pulmonary Therapies May 19, 2009:1837–51cross the mitral annulus and use a cinching cable to reduce
he septal-lateral dimensions of the mitral annulus. The
nvestigational strategy has been to demonstrate efficacy in
umans using a surgical approach before developing fully a
ercutaneous delivery system.
Acute and chronic animal studies of the AccuCinch
evice have shown no evidence of acute trauma to the
eaflets of the mitral valve or LV outflow tract obstruction.
istological studies observed normal tissue healing sur-
ounding the site of implantation of the device. Two
urgical patients treated with the device so far have shown
ustained reductions in MR severity (2 to 0) at 6- and
2-month follow-up. In both cases, the surgery was adjunc-
ive to primary coronary artery bypass surgery. The company
s performing human cineangiographic studies with its
uide catheter to understand the shapes, angles, and views.
irst-in-man studies of the AccuCinch device are planned
or 2009.
uantumCor. The QuantumCor device (QuantumCor)
ses subablative radiofrequency energy to induce heating
nd shrinkage of the collagen of the mitral annulus. This
esults in remodeling and reduction of the septal-lateral
imensions of the mitral annulus. The initial prototype of
he QuantumCor device involves a catheter with an end-
oop diameter of 40 mm that has 7 electrodes along with 14
hermocouples measuring 3 mm in length with 2-mm
pacing (Fig. 4). Acute and chronic studies in sheep have
hown relative reductions in septal-lateral dimensions of up
o one-fifth (34). Acute histopathology specimens have
ocumented no injury to the mitral leaflets or coronary
inus. First in-man studies are planned.
ndirect Annuloplasty Techniques
oapsys. The Coapsys or iCoapsys (Myocor) LV reshap-
ng device was designed to be delivered surgically via an
pen-chest procedure (Coapsys) or percutaneously through
subxiphoid pericardial approach (iCoapsys). (Editor’s
ote: On October 30, 2008, Myocor sold its intellectual
roperty to Edwards Lifesciences Corp., which, according
o news reports, has no plans to continue trials of the
oapsys surgical system. However, the devices represented
n important concept and are included in this discussion.)
The Coapsys surgical system consists of an externally
laced epicardial posterior pad and an anterior pad
ridged by a cord that is covered with polytretrafluoreth-
lene (Fig. 5). The posterior pad has 2 heads, 1 posi-
ioned at the level of the mitral annulus and 1 at the level
f the papillary muscles. The Myocor device results in: 1)
eshaping of the LV and reduction in the dimensions of
he septal-lateral dimensions of the mitral annulus; and
) superior displacement of the papillary muscles in a
ore subvalvular position. These changes address the 2
ain pathophysiological mechanisms of functional MR:Figure 3 The Mitralign System (Mitralign, Inc.)
(A) Illustration depicting the therapy catheter with a deflectable end
inserted retrograde across the aortic valve into the left ventricle and posi-
tioned in a subvalvar mitral position. (B and C) Tethering and tension on
the system brings the anchors in closer proximity, resulting in a reduction
in the septal-lateral dimensions of the mitral annulus.nnular dilatation and LV remodeling associated with
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May 19, 2009:1837–51 Transcatheter Mitral and Pulmonary Therapiesapillary muscle displacement, leaflet tethering, and leaf-
et malcoaptation.
A prospective, nonrandomized feasibility study in hu-
ans with functional ischemic MR (TRACE study
TRAndolapril Cardiac Evaluation]) has been completed,
emonstrating significant acute and midterm reductions in
R grade (3 to 1) and improved LV remodeling indices
t 1-year follow-up (35).
RESTOR-MV (Randomized Evaluation of a Surgical
reatment for Off-Pump Repair of the Mitral Valve) is a
rospective, multicenter, pivotal U.S. Food and Drug Ad-
inistration trial randomizing patients with coronary artery
isease and functional MR to surgical revascularization and
eduction annuloplasty or surgical revascularization and
Figure 4 QuantumCor Device (QuantumCor, Inc.)
Early prototype of end-loop catheter used in open-chested
animal models. A percutaneous system is under development.oapsys annuloplasty. The primary end point at 1 yearncludes reduction in MR severity and change in indices of
V remodeling. To date, 138 patients have undergone
andomization, and preliminary acute results have shown
imilar improvements in MR grade (3 to 1) and
eductions in anteroposterior dimensions of the mitral
nnulus (3.45  0.39 cm to 2.34  0.37 cm vs. 3.40  0.27
m to 2.85  0.34 cm) with either approach.
The iCoapsys system is delivered through a subxiphoid
ericardial approach under fluoroscopic and angiographic
uidance. A specifically designed needle, guidewire, and
heath are used to obtain controlled access into the pericar-
ial space. A needle is passed transventricularly to allow
assage of a flexible wire and eventually, a transventricular
ord is passed and exteriorized. Once implantation is
omplete, the sizing cord is used to alter the geometry of the
V until the desired reduction in mitral regurgitation is
chieved (36).
A prospective, nonrandomized, single-arm feasibility evalu-
tion of the iCoapsys System (the VIVID [Valvular and
entricular Improvement Via iCoapsys Delivery] study) was
nitiated in 2008 for patients with functional MR.
ercutaneous septal sinus shortening. This device, also
nown as PS3 (Ample Medical), consists of an atrial septal
ccluder device and T-bar element that act as anchors in the
nteratrial septum and coronary sinus, respectively (Fig. 6A).
bridging element traversing the left atrium connects the 2
nchors (Fig. 6B). Specialized catheters, known as Magn-
caths, incorporate corresponding shaped magnets at their
istal tip; these are placed in the coronary sinus and left
trium. After magnetic linking of both Magnecaths, a
rossing catheter is advanced from the left atrial catheter
nto the coronary sinus catheter. The T-bar element is
dvanced into the coronary sinus and the bridging element,
ttached to the T-bar, is pulled back across the transseptal
uncture. Finally, the atrial septal occluder device is de-
loyed over the bridging element and tension is applied to
isplace the coronary sinus toward the atrial septum. This
Figure 5 The iCoapsys Device (Myocor)
The device (no longer in development) consists of an externally placed epicar-
dial posterior pad and an anterior pad bridged by a cord covered with poly-
tretrafluorethylene (PTFE). Tension on the cord decreases the septal-lateral
dimensions of the mitral annulus.
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alve annulus.
Studies using the PS3 in a sheep model of functional MR
emonstrated acute and chronic reductions in septal-lateral
imensions of the mitral annulus by up to one-quarter and
eductions in MR from 2 to 1 (37). Subsequently, 2
atients have undergone temporary implantation of the PS3
evice before clinically indicated mitral valve repair surgery
38). In the first patient, with severe aortic insufficiency and
oderate functional MR, a reduction in MR grade from 2
o 1 and a decrease in septal-lateral dimensions from 38 to
7 mm (29% relative change) were observed. The second
atient, who had severe functional MR and multivessel
oronary artery disease, also experienced significant reduc-
ions in MR grade from 3 to 1 and a decrease in
eptal-lateral dimensions of the mitral annulus from 36 to
5 mm (31% relative change). In both patients, no proce-
ural complications were observed and removal of the device
t surgery was uneventful. The final generation device has
een tested in animals and the company plans to initiate
hase I clinical trials in late 2008 and early 2009.
ranscatheter Coronary Sinus Techniques
ranscatheter coronary sinus techniques use a reshaping
evice implanted in the coronary sinus to reduce the
eptal-lateral dimensions of the mitral annulus. The spatial
elationship between the coronary sinus and mitral valve
nnulus plays a crucial role in these procedures (39).
Several aspects of the coronary sinus-mitral valve annulus
re of note. In the majority of cases, the coronary sinus is
Figure 6 The Percutaneous Septal Sinus Shortening (PS3) Dev
(A) The device consists of an atrial septal occluder device and T-bar element that act
septum and coronary sinus, respectively. (B) A bridging element traversing theocated superior to the level of the mitral annulus, often in rirect contact with the posterior left atrial wall (40–42).
he smallest and largest separation distance between the
oronary sinus and mitral annulus is usually located near the
nterolateral commissure (i.e., distal coronary sinus) and
nteromedial commissure (i.e., proximal coronary sinus),
espectively (40–44). The crossover frequency between the
eft circumflex coronary artery and coronary sinus can range
rom 63.9% to 80.8%. Thus, the coronary sinus device can
otentially compress and limit flow in the coronary artery
41,42,45). It is important to note, however, that crossing of
he coronary arteries does not necessarily result in compro-
ised coronary atrial flow. Last, variability exists in the
ranching points of the coronary venous tree. Although not
et confirmed, these subtleties can result in suboptimal
eformation of the mitral annulus and inadequate reduc-
ions in MR.
ONARC. The Edwards MONARC device (Edwards
ifesciences Corp.) is implanted in the coronary sinus via
he right internal jugular vein. The support frame is con-
tructed of nitinol. Intervening between the proximal and
istal stent anchors is a spring-like bridging segment that
ontains biodegradable material (Fig. 7). A few weeks after
mplantation, resorption of the biodegradable material
auses shortening of this bridging segment, bringing the
roximal and distal anchors closer together and displacing
he posterior mitral annulus more anteriorly. The net effect
s a reduction in the septal-lateral dimension of the mitral
alve annulus.
Human experience with the first-generation Viking an-
uloplasty device (Viking Systems, La Jolla, California) was
mple Medical)
hors in the interatrial
trium connects the 2 anchors.ice (A
as anc
left aeported by Webb et al. (46); 4 of 5 patients with chronic
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patient had perforation of the anterior interventricular
ein. In those with a functioning device at last follow-up,
ean MR grade decreased from 3.0  0.7 to 1.6  1.1.
hree patients had separation of the nitinol bridge segment
t 22, 28, and 81 days post-implantation.
The now completed EVOLUTION phase I study en-
olled patients with functional MR and heart failure. The
ONARC device used in this study was designed with a
einforced bridging segment. Implantation success was
chieved in 59 of 72 patients (82%) (47). Freedom from
eath, MI, and cardiac tamponade at 30 days was 91% (n
7). At 90 days, freedom from death, MI, cardiac tampon-
de, coronary sinus thrombosis, device migration, device
mbolization, or pulmonary embolus was 86%. Of note,
-month follow-up angiography revealed coronary artery
ompression in 15 of 50 patients (30%); 3 patients experi-
nced an MI resulting in 1 death. Major adverse events at
8-month follow-up included 1 death, 3 MIs, 2 coronary
inus perforations, 1 anchor displacement, and 4 anchor
eparations.
Based on the evidence, the MONARC system is feasible
o implant. Although efficacy data are encouraging, coro-
ary compression and anchor separation are important
afety concerns. Screening of patients and design iterations
ay solve these problems. A nonrandomized, multicenter,
rospective safety and efficacy study (EVOLUTION phase
I) is planned for the near future.
TMA device. The Percutaneous Mitral Annuloplasty
evice (PTMA) (Viacor) consists of a 7-F multilumen
elivery catheter that is placed in the coronary sinus. Up to
rods of varying stiffness, length, and tapers can be inserted
nto the parallel lumens of the delivery catheter to vary the
ension of the delivery catheter (Fig. 8). In contrast to the
ONARC system and CARILLON Cardiac Mitral Con-
our system (see the following text), this device exerts an
utward force at its proximal and distal segments (i.e.,
Figure 7 MONARC System (Edwards Lifesciences Corp.)
The support frame is constructed of nitinol. Intervening between the proximal
and distal stent anchors is a spring-like bridging segment with memory charac-
teristics and biodegradable material.ommissural points) resulting in anterior displacement of (he P2 segment and a decrease in the septal-lateral dimen-
ions of the mitral annulus.
The PTMA device has been tested in animal models of
schemic MR (48,49), with evidence of significant reduc-
ions in the septal-lateral dimensions of the mitral annulus,
itral valve tenting area, and mitral regurgitation. In a
emporary implant study of 4 patients with ischemic car-
iomyopathy and MR, successful device implantation was
chieved in 3 patients (50). There was a reduction in the
ffective regurgitant orifice area (0.25  0.06 cm2 to 0.07 
.03 cm2), regurgitant volume (45.5  24.4 ml to 13.3 
.3 ml), and septal-lateral dimensions of the mitral annulus
40.75  4.3 mm to 35.2  1.6 mm).
The phase I PTOLEMY (Percutaneous TransvenOus
itral AnnuloplastY) trial enrolled 27 patients with heart
ailure (New York Heart Association functional class II to
V) and moderate to severe functional mitral regurgitation
rom 5 centers in Europe and Canada (51). Eight patients
ere excluded before implantation because of unsuitable
oronary sinus anatomy. Of the 19 patients who underwent
mplantation, 13 had a reduction in MR severity and in 6,
he device was ineffective (Table 2). Four patients subse-
uently required removal of the device: 1 patient at day 7 for
evice fracture and 3 patients referred to surgery because of
evice migration and/or diminished efficacy. Five patients
18.5%) had long-term implants with reductions in MR
everity. Following the completion of the phase I studies
nd the ensuing device iterations, the PTOLEMY II trial is
urrently underway and will treat up to 60 patients at
nvestigational sites in Europe, Canada, and the U.S.
atients with moderate to severe mitral regurgitation,
YHA functional class II to IV, and LV dysfunction (LV
jection fraction 25% to 50%) will be included.
ARILLON. The CARILLON Mitral Contour System
Cardiac Dimensions) consists of a proximal and distal
elical anchor connected by a curved nitinol bridge that is
mplanted in the coronary sinus (Fig. 9). The right internal
ugular vein is cannulated with a 9-F catheter to access the
oronary sinus. After deployment of the distal anchor in the
reat cardiac vein, tension is applied by pulling on the
ystem, resulting in cinching of the mitral annulus. After the
esired effect is achieved, the proximal anchor is deployed
nd the device is uncoupled from the delivery catheter
ystem. The proximal and distal anchors may be deployed
nd subsequently recaptured in the event of malpositioning
r inadequate efficacy.
Animal safety and feasibility studies demonstrated acute
nd chronic reductions in the diameter of the mitral annulus
nd reductions in the ratio of MR to left atrial area (16 
to 4  1) (52–54).
In the European phase I AMADEUS (CARILLON
itral Annuloplasty Device European Union Study) trial
55), implantation success was achieved in 30 of 43 patients
70%) and 80% of patients had at least a 1-grade reduction
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Transcatheter Mitral and Pulmonary Therapies May 19, 2009:1837–51n MR severity (Table 2). Major adverse events at 1-month
ollow-up included 1 death, 2 MIs, 2 coronary sinus
erforations, 1 dissection, 1 anchor displacement, and 1
ontrast nephropathy. Coronary arteries were crossed in 36
atients (84%). Arterial compromise contributed to lack of
mplantation in 6 patients (14%). All unsuccessful implants
ere recaptured and removed in these patients without
Figure 8 The PTMA Device (Viacor)
(A) Proximal component and (B) distal components. Up to 3 rods of varying stiffne
of the delivery catheter to vary the tension in the catheter and on the mitral annul
Figure 9 The CARILLON Mitral Contour System (Cardiac Dimen
Device consists of a proximal and distal helical anchor connected by a curved nitinomplications. Of note, not all crossed coronary arteries
esulted in compromised coronary artery flow.
Glimpse Into the Future
number of transcatheter mitral valve therapies are cur-
ently in developmental stages: transcatheter mitral valve
ngth, and tapers can be inserted into the parallel lumens
FE  polytetrafluorethylene; PTMA  percutaneous mitral annuloplasty.
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May 19, 2009:1837–51 Transcatheter Mitral and Pulmonary Therapieseplacement (e.g., Endovalve Hermann or Lutter mitral
alve), percutaneous neochordal implantation (56), and
ybrid surgical-transcatheter strategies (e.g., a surgically
mplanted prosthetic annular ring that can, in case of future
eed, be adjusted mechanically in the catheterization labo-
atory percutaneously).
ulmonary Valve Therapies
he pulmonary valve, often thought to be the least impor-
ant valve in the heart, has long been ignored in the adult
opulation. Disease of this valve was believed to have little
mpact on patient morbidity and mortality. This is, in fact,
ot the case, particularly in the subset of patients with
ongenital heart disease. Tetralogy of Fallot accounts for
pproximately 10% of all forms of congenital heart disease
nd is associated with varying degrees of pulmonary ob-
truction ranging from pulmonary atresia to right ventricu-
ar outflow tract (RVOT) obstruction. Reparative options in
hese patients have focused on increasing pulmonary blood
ow using various surgical techniques including homograft
onduits and transannular patches.
Unfortunately, long-term follow-up suggests that these
echniques are associated with serious complications once
hought to be benign. Severe pulmonary insufficiency, for
xample, results in right ventricular (RV) volume over-
oad, dilation, and failure, thereby increasing the risk of
rrhythmias and sudden death. In addition, homograft
ulmonary valve stenosis is associated with the develop-
ent of RV hypertension and arrhythmias. These com-
lications often require further surgical intervention that
omes at the cost of additional morbidity and mortality.
n this group of young patients, multiple additional
rocedures may be required during their lifetimes, which
as led to interest in developing a nonsurgical technique
or percutaneous placement of a biological valve in the
ulmonary position.
arly work. Development of a percutaneous pulmonary
alve was pioneered by Bonhoeffer and his group’s work
ith lambs. They used a biological valve harvested from the
ugular veins of fresh bovine cadavers. These valves were
icuspid or tricuspid, with extremely thin leaflets. The
alves were prepared by trimming the venous wall to
liminate any extraneous tissue and reduce the valve profile.
hese valves were then sutured to a vascular stent composed
f platinum and iridium. For implantation the valve was
and-crimped onto a balloon catheter ranging from 18 to 22
m in length. The balloon catheter was chosen to approx-
mate the size of the pulmonary artery as measured on
ngiography. The position of the valved stent was easily
isualized using fluoroscopy and the stent was then balloon-
xpanded and deployed in the native pulmonary valve of the
amb to fix the device on the pulmonary wall. The balloon
as subsequently deflated and the catheter removed, leaving
he replacement valve in the desired position. The procedure
as carried out successfully in 5 animals with no complica-ions, demonstrating that percutaneous pulmonary valve im-
lantation was possible in animals and perhaps humans (57).
The first implantation of a pulmonary valve in a human
as carried out by Bonhoeffer et al. (58) in 2000. The
atient was a 12-year-old boy with a history of congenital
eart disease and a previous RV-to-pulmonary artery con-
uit that had become stenotic with moderate insufficiency
eading to moderate RV dilation. The procedure, performed
nder general anesthesia, used hemodynamic and angio-
raphic evaluation of the conduit was used to determine the
everity and location of stenosis. A right coronary catheter
as placed in a distal branch pulmonary artery, and a
uper-stiff exchange guidewire (Amplatz, Meditech, Water-
own, Massachusetts) was positioned in the distal pulmo-
ary artery. The valve assembly, composed of the valved-stent
nd balloon-in-balloon catheter, was then passed over the
uidewire and advanced into the pulmonary artery. Once in an
cceptable position, the sheath was withdrawn to expose the
tent crimped on the balloon. The inner balloon was initially
nflated followed by the outer balloon, thus deploying the
alved stent. The inner and the outer balloons were then
apidly deflated and the balloon catheter was removed,
eaving the guidewire in place (Fig. 10). The procedure was
ncomplicated and the patient was discharged home the
ollowing day. On follow-up, the child was asymptomatic
ith complete relief of conduit insufficiency and mild
esidual stenosis secondary to severe conduit calcification.
After this initial successful implant in a human being,
onhoeffer et al. (59) reported the first series of percutane-
us pulmonary valve implantations in 8 patients with
urgically repaired congenital heart disease and resultant
onduit pulmonary valve disease. All patients were symp-
omatic with effort intolerance and breathlessness, and
eeded conduit replacement because of significant stenosis
Figure 10 The Melody Pulmonary Valve (Medtronic)
Angiogram (lateral projection) of the main
pulmonary artery after implantation of the Melody valve.
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Transcatheter Mitral and Pulmonary Therapies May 19, 2009:1837–51nd/or pulmonary regurgitation. The procedures were per-
ormed in the manner discussed previously with the excep-
ion that manual inflation of a balloon (Zmed II 1 84,
umed Inc., Nicholville, New York) was performed in the
VOT to determine whether there was sufficient room to
mplant a pulmonary valve without creating additional
bstruction in the conduit.
The valved stent was successfully implanted in all 8
atients. After implantation, angiographic evaluation con-
rmed competence of the newly implanted valve in 6
atients. Two patients had suboptimal valve placement
esulting in an insignificant paraprosthetic leak. Hemody-
amic improvement was seen in 5 of 8 patients, with partial
elief of obstruction in 3 patients. There were no major
rocedural complications and all patients were discharged
etween 1 and 5 days after the procedure. Echocardio-
raphic follow-up at a mean of 10 months demonstrated
ood valve function, with improvement in RV size and
unction as well as clinical improvement based on relief of
ymptoms and improved functional capacity in those with
omplete relief of obstruction.
This study demonstrated the feasibility and safety of the
ercutaneous approach for replacement of the pulmonary
alve and, in this group of patients, demonstrated that relief
f pulmonary insufficiency was associated with improve-
ents in RV function, perhaps leading to subsequent
eneficial effects on arrhythmia reduction.
Certain limitations remain; in particular, the procedure
ay not provide adequate relief of obstruction in patients
ith severely calcified or small conduits. In addition, for
hose with large or aneurysmal conduits, there may be an
pper limit of size for which this procedure will be suitable.
he longevity of such valves is also unclear and will require
ong-term follow-up studies.
ongenital heart disease. This successful initial series
rompted further study of percutaneous pulmonary valve
eplacement in congenital patients with a history of RVOT.
larger series of 59 patients with pulmonary regurgitation
ith or without stenosis after repair of congenital heart
isease followed in 2005 (60). Patients were considered for
articipation if they had previously undergone RVOT
urgery during repair of congenital heart disease and had
ymptoms or RVOT dysfunction of a sufficient degree to
arrant surgical intervention on the basis of conventional
ndications: RV hypertension (two-thirds of systemic blood
ressure or greater) with outflow tract obstruction, signifi-
ant pulmonary insufficiency, RV dilation, or RV failure.
xclusion criteria included patients 5 years of age or
eighing 20 kg, pregnancy, occluded central veins, active
nfection, and outflow tracts with RVOT diameter22 mm
n angiography, or conduits 16 mm in diameter at
urgical insertion.
Fifty-nine patients were recruited for percutaneous pul-
onary valve implantation with the Melody bovine jugular
ein valve (Medtronic, Minneapolis, Minnesota). The me-
ian age was 16 years (range 9 to 43 years) and median seight 56 kg (range 25 to 110 kg); 36 patients (61%) had
ariants of tetralogy of Fallot, the majority of whom had
ulmonary atresia (n  18), 3 with absent pulmonary valve
yndrome, and the rest with severe pulmonary stenosis.
ost patients had a homograft conduit after surgery to the
VOT (46 of 59, 78%). Three patients had a “native”
VOT that had been augmented with a pericardial or
omograft patch.
Pulmonary valve implantation was successful in 58 of 59
atients. There were 3 significant early complications. In 2
atients, the stent dislodged over the guidewire, and both had
uccessful surgical homograft implantation. There was 1 life-
hreatening bleed due to dissection of the homograft that
equired emergent surgical intervention. Minor complications
ncluded minor dissection of the homograft (n  1, treated
onservatively), detachment of the distal tip of delivery system
n  2) into the branch pulmonary artery (snared successfully
nd retrieved), and local bleeding (n  4).
Mean follow-up was 9.8  1.4 months and there was no
eported mortality. Follow-up echocardiography demon-
trated sustained hemodynamic improvements in all pa-
ients with a history of stenosis. The improvement in
egurgitation also was sustained, with only 1 patient having
oderate regurgitation because of endocarditis of the valve.
agnetic resonance imaging showed significant reduction
n pulmonary regurgitant fraction and in RV end-diastolic
olume as well as a significant increase in LV end-diastolic
olume and effective RV stroke volume.
There were device-related problems during follow-up in
4 patients. In-stent stenosis was observed in 7 patients
ecause of a problem with valve apposition within the stent.
he problem may have been secondary to failure to suture
he valve to the entire length of stent in the initial design
f the device. This led to device explantation in 3 patients;
owever, with further experience, these patients were later
reated with a second percutaneous valve implantation.
tent fracture was observed in 7 patients at a median of 9
onths after the procedure, but this was associated with
nly 2 clinical events. There was 1 incident of late stent
mbolization to the right pulmonary artery 9 months after
he procedure.
Recently published data on the previous cohort, now
xpanded to 155 congenital heart disease patients, illus-
rated the impact of changing technology and operator
earning curve on the success of this procedure (61). Be-
ween 2000 and 2007, 163 patients were evaluated for
ercutaneous pulmonary valve replacement, with 155 pa-
ients eventually undergoing the procedure. Median age of
he cohort was 21.2 years (range 7 to 71 years); 37% of
atients were 16 years old, and 42% were female. The
ajority of patients had a diagnosis of tetralogy of Fallot
61%) and the anatomic substrate was an RV-pulmonary
rtery conduit in 92% of patients.
All patients were assessed using transthoracic echocardi-
graphy, magnetic resonance imaging, or angiography. In
ome cases simultaneous coronary angiography was per-
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valuate the risk of coronary compression by percutaneous
alve implantation.
Results of the cohort were divided into 2 groups (the first
0 patients and the remaining 105 patients) in order to
emonstrate a difference in the learning curve and improved
echnology. The first 50 patients were believed to represent
he learning curve because many design and protocol
hanges took place with this initial group of patients. The
rocedure was successful in the majority of these early
atients; however, there were 7 major complications includ-
ng homograft rupture, coronary compression, device dis-
odgment, and embolization with obstruction of the right
ulmonary artery. None of these complications resulted in
ortality, although 5 patients required surgical intervention
f the RVOT.
Median follow-up was 28.5 months (range 0 to 83.7
onths) and data were available on all patients with respect
o mortality, reoperation, and repeat transcatheter interven-
ion. Four of 155 patients who underwent percutaneous
ulmonary valve implantation died, and survival at 83
onths was 96.6%. Freedom from transcatheter reinterven-
ion decreased from 95  2% at 10 months to 73  6% at
0 months. Repeat interventions included balloon dilatation
nd placement of a second valve within a valve. Reasons for
eintervention included stent fracture, residual gradient, and
alve restenosis. Follow-up echocardiography demonstrated
ood valve function with, at worst, mild regurgitation and
redominantly trivial or absent pulmonary regurgitation in
ore than 100 patients.
Analysis of the data with respect to the impact of the
earning curve suggested improved patient selection, lower
ccurrence of a residual gradient due to aggressive post-
ilatation of the device after deployment, and treatment of
evice failures with a second device as opposed to reopera-
ion. The incidence of procedural complications also de-
reased, from 6% in the earliest group of patients to 2.9% in
he second (3 of 50 patients vs. 3 of 105 patients). However,
here was no difference in transcatheter reintervention
etween the 2 groups. This was attributed to the require-
ent of additional interventions due to stent fracture, a
omplication not related to the learning curve of the
rocedure. These studies illustrate the success of percutane-
us valve implantation in patients with both stenotic and
egurgitant lesions, as well as the problems that can be
ssociated with this technology and the work that remains.
One of the obvious current limitations of this procedure
s the size of the RVOT. This study excluded patients with
n outflow tract larger than 22 mm in diameter due to
oncerns over valve stability and competence if implanted in
larger outflow tract. Work is already underway in animal
odels to develop a nitinol stent housing a bioprosthetic
alve that can be implanted in larger outflow tracts without
ompromising valve function (62). In addition, complications
uch as stent fracture, which occurred in 21% of patients, will
equire monitoring with serial radiographs and echocardiogra-hy after valve implantation. Research has identified the
ollowing factors associated with a higher risk of stent fracture:
mplantation into a “native” RVOT, the absence of calcifica-
ion along the RVOT, and recoil of the percutaneously
mplanted pulmonary valve after deployment (62).
Finally, the question of valve longevity remains. Current
ata confirm that the bovine jugular valve functions well at
median of 29 months, yet this valve will likely suffer from
he same degenerative processes that affect other biological
alves. Until longer-term data are available, patients will
ave to be closely monitored for signs of valve failure.
Overall, these initial results in percutaneous pulmonary valve
eplacement are encouraging for the field of transcatheter
ntervention, but long-term follow-up is essential to under-
tand the overall impact of this technology on patients.
onclusions
ranscatheter valve therapy provides a minimally invasive
pproach compared with existing alternatives, with the
bility to address a significant number of patients and have
positive impact on their lives. However, many questions,
emain: What are the indications/contraindications for
hese procedures? What are the patient selection criteria?
hat are the short- and long-term complications (safety)?
hat are the short- and long-term benefits (efficacy)? What
re the cost implications? What type of pivotal study designs
re needed to adequately evaluate these therapies?
One thing is certain: The widespread implementation of
ranscatheter technology will require a heart team approach
i.e., interventional cardiologists and cardiac surgeons) to
nderstand where these new therapies will fit into the
anagement of valvular heart disease. Fortunately, both the
nowledge and limitations of the cardiac surgeon and
nterventional cardiologist are complementary; conse-
uently, when they perform as a team, it is the patient who
ltimately benefits the most.
eprint requests and correspondence: Dr. Raoul Bonan, Institut
e Cardiologie de Montreal, 5000 East Belanger, Montreal, H1T
C8 Quebec, Canada. E-mail: raoul.bonan@mmic.net.
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